Aptus Pharma Reports Strong H1 Performance with Revenue Doubling to INR 48.92 Crore
Aptus Pharma Ltd 路 Financial Result 路 21 Oct 2026, 12:59 am
Aptus Pharma Reports Strong H1 Performance with Revenue Doubling to INR 48.92 Crore Aptus Pharma approved unaudited results for the half year ended 30th Sep'26, reporting revenue from operations of INR 48.92 crore (up 240% YoY from INR 14.38 crore), EBITDA of INR 7.68 crore, and PAT surging to INR 5.08 crore versus INR 1.75 crore in the prior period. EPS stood at INR 2.96. The company approved a preferential equity issue of 16.03 lakh shares at INR 280 each, aggregating INR 44.88 crore, awaiting BSE approval. Management targets 46% geographic coverage across India by Mar'27.
Original exchange filing (PDF)
More announcements from Aptus Pharma Ltd
- Outcome of Board Meeting - Allotment of Equity Shares on Preferential Basis under Regulation 30 of SEBI LODR Regulations, 2015 路 12 Nov 2026
- Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting for .... 路 06 Nov 2026
- Receipt of In-Principle Approval for Preferential Issue 路 31 Oct 2026
- Transcript for Earning Call for the Quarter and Half Year ended on September 30, 2026 路 30 Oct 2026
- Audio recording of the Earnings Call dated October 26, 2026 路 27 Oct 2026
- Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 路 23 Oct 2026
- Intimation of Earnings Call for the quarter and half year ended September 30, 2026 路 26 Oct 2026
- Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company .... 路 21 Oct 2026
